Novavax Surges 12.63% Post-Earnings: Strong Momentum and Positive Outlook Ahead

Technical Analysis

Novavax (NVAX) closed at $7.58 on August 6, 2025, up 12.63% from the prior session, signaling strong short-term bullish momentum. The intraday range was $7.21 to $8.23. The 14-day RSI at 59 remains below overbought territory, suggesting room for further upside. The price sits above the 50-day moving average ($6.95) but slightly below the 200-day average ($7.77), indicating a mixed medium-to-long-term trend. MACD is positive at 0.23, reinforcing bullish momentum. Notably, average daily volume nearly triples today's volume of 23.14 million shares, which may imply some profit-taking or consolidation ahead. Key support lies at $6.73, with immediate resistance near $7.68 – a break above this could trigger additional buying pressure. The ATR of 5.63 appears anomalously high relative to price levels, likely indicating recent volatility spikes.

For the next trading day (August 7), momentum signals favor continuation of gains, potentially testing the intraday high of $8.23 or slightly above, but volume contraction may temper aggressive moves. Over the coming week, given the positive technical indicators combined with heightened market attention post-earnings, the stock is poised to trend in the $7.50–8.50 range barring adverse market developments.

Fundamental Analysis

Novavax reported Q2 2025 earnings of $0.62 per share, significantly surpassing the consensus loss estimate of $0.07 and demonstrating a substantial recovery from $0.99 EPS in the prior year, albeit down year-over-year. Total revenue of $239 million exceeded expectations, bolstered by a $175 million milestone payment tied to FDA Biologics License Application (BLA) approval of Nuvaxovid™, the first recombinant protein-based non-mRNA COVID-19 vaccine in the U.S. This approval catalyzed a commercial transition with Sanofi handling leadership for the 2025-2026 vaccination season, reducing Novavax’s operational burden.

The company’s PE ratio stands at an exceptionally low 2.76, suggesting the stock may be deeply undervalued relative to earnings, though this low multiple could reflect investors’ concerns about future revenue sustainability post-COVID vaccination cycle peak. The pipeline shows promise with combination COVID-19/influenza vaccines entering Phase 3 trials, delivering data indicative of strong immune responses and T-cell activity, which may diversify future revenue streams. The updated 2025 revenue guidance signals operational confidence backed by positive clinical progress.

Analyst consensus remains constructive with 16 buys and 4 holds versus only 2 sells, placing the consensus price target median at $22 and consensus at $50.8, highlighting a strong perceived upside potential from current levels.

Intrinsic value, judging by normalized earnings and growth prospects, implies considerable upside. Novavax’s ability to leverage milestone-driven revenues with emerging vaccine candidates suggests a fair value substantially above the current market price, especially as the company transitions from pandemic-related revenue peaks to diversified immunization solutions.

Stock Performance Outlook

Next trading day: Market reaction to earnings momentum combined with technical signals points to a bullish open, with potential testing of $8.20–$8.50 resistance. Watch for volume trends and intraday retracements near the stop-loss of $7.29.

Upcoming week: Expect a consolidation phase with upward bias, likely maintaining a trading range between $7.50 and $8.50 driven by positive fundamental catalysts and technical strength.

Long-term, the stock depends on successful commercialization of new vaccine candidates and sustained milestone payments or partnerships. Risks include regulatory dynamics, competitor innovation, and the cyclical nature of COVID vaccine demand.

Overall Evaluation

Novavax exhibits strong earnings beat and revenue growth, a robust product pipeline, and favorable analyst sentiment. The technicals confirm intermediate bullish momentum with manageable risk levels. Despite volatility and sector-specific risks, the combination of undervaluation (PE 2.76), upside analyst targets, and successful milestone catalysts support a positive outlook.

Categorizing the stock as a "Buy" candidate reflects the current valuation disconnect with fundamental performance and growth prospects. Continued monitoring of clinical trial progress and market reception post-Sanofi transition remains key to validating long-term intrinsic value realization.